GLG Network Survey: Rare Diseases

Please fill out the form to request access to the survey data

SURVEY DETAILS
TARGET POPULATION

For this Network Survey, GLG surveyed 70 senior executives working in biotech and pharmaceutical companies across the US and Europe (UK, France, Italy, Spain, and Germany).

What will you learn from this survey?

  • Respondents assessed the current and future rare disease treatment market and discussed the areas of rare diseases where their organization is conducting research or clinical trials.
  • The research explored the trial design challenges the respondents face and the potential restrictions they could encounter in orphan disease drug development.
  • Lastly, experts discussed the time required for drug approval from regulatory bodies and the potential changes in policies regarding drug development over the next five years.

Examples of findings:

  • 86%, 74%, and 67% of respondents whose organizations are conducting trials for rare skin disorders, rare cancers, and infectious diseases, respectively, reported that the drug is in the clinical trial phase.
  • At least half of each country’s respondents believe the market size will continue to increase by under 20% in the next 2 years.
  • 70% of experts believe that AI advancements will generate greater insights from real-world data in the drug discovery process.

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Vince Thomas, former Global Economic Strategy Leader at Roche Diagnostics Ltd.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • What are the key value drivers in the drug development process?
  • What role do you see for technology in the context of rare diseases?
  • How important is cross-industry collaboration for drug development?
  • In what way does investment in market preparedness best enhance an organization’s effectiveness in addressing rare diseases?
  • How do organizations in your industry approach ROI calculation for rare disease drug development?
  • How do you expect regulatory policies regarding drug development for rare diseases to change in the next 5 years?
  • For which rare disease area do you think a drug will be developed in the next five years?

Access

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.